Brief: Carl Zeiss Meditec Cuts FY 23/24 Outlook Revenue And EBIT

Carl Zeiss Meditec AG

17/06/2024 09:13

June 17 (Reuters) - CARL ZEISS MEDITEC AG  AFXG.DE :
    * REVENUE AND EBIT FORECAST FOR FISCAL YEAR 2023/24 REDUCED
AMID
SLOWER THAN EXPECTED RECOVERY OF EQUIPMENT BUSINESS
    * IN COMBINED MONTHS OF APRIL AND MAY 2024, ORDER ENTRY,
REVENUE
AND EBIT CONTINUED TO FALL SHORT OF PREVIOUS YEAR'S LEVEL
    * REVENUE IS NOW EXPECTED TO REACH AROUND EUR 2,000 MILLION
    * OUTLOOK 2023/2024: EBIT (EXCLUDING EFFECTS RELATED TO DORC
ACQUISITION) WILL FALL SIGNIFICANTLY SHORT OF PREVIOUSLY STATED
TARGET OF A COMPARABLE LEVEL TO LAST YEAR (EUR 348.1 MILLION)
AND REACH A LEVEL BETWEEN AROUND EUR 215 MILLION UP TO AROUND
EUR 265 MILLION
    * MANAGEMENT IS TAKING FURTHER MEASURES TO REDUCE OPERATING
EXPENSES
    * A FURTHER UPDATE WILL BE PROVIDED WITH Q3 2023/24 RESULTS
ON
AUGUST 6, 2024
    * MIDTERM GOALS UNCHANGED
    * SLOWER THAN ANTICIPATED ROLL-OUT OF NATIONAL VOLUME-BASED
PROCUREMENT FOR INTRAOCULAR LENSES IN CHINA IS ALSO CAUSING AN
ADDITIONAL HEADWIND TO REVENUE AND EBIT

Source text for Eikon:  ID:nEQ3NGBWwa 
Further company coverage:  AFXG.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))